文献速递骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌肥胖与代谢综合征

WHI研究回顾:绝经激素治疗的风险与获益再评估

Then and Now: What We Have Learned From the WHI.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文为叙述性综述,通过结构化PubMed检索汇总WHI研究数据,重新评估绝经激素治疗(MHT)在绝经后女性中的风险与获益。WHI数据显示联合CEE-MPA与单用CEE均显著降低骨折风险,心血管结局受启动时机影响,支持「机会窗」假说,且不同方案对乳腺癌和结直肠癌风险影响不同。结论强调MHT应个体化、时机敏感地使用。

要点

  • 联合CEE-MPA与单用CEE均显著降低髋部、椎体和总骨折风险。
  • 60岁前或绝经10年内启动MHT可能心血管获益,≥65岁启动则风险增加。
  • CEE-MPA增加浸润性乳腺癌风险,单用CEE对乳腺癌风险无显著影响。

核心结论

  • WHI研究强调MHT应个体化、时机敏感地使用,获益与风险受方案、启动时机和患者特征影响。

研究设计与样本

  • 叙述性综述,通过结构化PubMed检索MHT、骨骼、心血管代谢、癌症及认知结局相关临床试验、观察性研究和系统综述。

主要发现

  • 联合CEE-MPA和单用CEE均显著降低髋部、椎体和总骨折风险,补充钙和维生素D可进一步保护骨骼。
  • 心血管结局受启动时机影响:60岁前或绝经10年内启动可能获益,≥65岁启动增加冠脉事件和卒中风险。
  • CEE-MPA增加浸润性乳腺癌发生率(尤其既往使用者),单用CEE与乳腺癌风险 marginal 非显著降低相关。
  • 两种方案在积极治疗期间均降低结直肠癌发生率。
  • 早期启动MHT对认知功能无影响,晚期启动增加痴呆风险。

临床怎么用

  • 临床应基于患者年龄、绝经年限和个体特征,在机会窗内个体化启动MHT以最大化获益并降低风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: This narrative review aims to highlight key learning points from the Women's Health Initiative (WHI) studies, providing a nuanced appraisal of menopausal hormone therapy (MHT) risks and benefits in postmenopausal women. METHODS: A structured PubMed search was conducted using MeSH terms and keywords for MHT, bone health, cardiovascular and metabolic disease, cancer (breast, endometrial, ovarian, colorectal), and cognitive outcomes. The search included clinical trials, observational studies, and systematic reviews published in the English language. RESULTS: WHI data reveal that both combined conjugated equine estrogen-medroxyprogesterone acetate (CEE-MPA) and CEE-only therapy significantly reduce hip, vertebral, and total fracture risk, with further skeletal protection from calcium and vitamin D co-administration. Cardiovascular outcomes are strongly influenced by timing: initiation before age 60 or within 10 years of menopause may confer benefit, while delayed initiation (≥65 years) increases risks of coronary events and stroke, supporting the "window of opportunity" hypothesis. CEE-MPA therapy increases invasive breast cancer incidence (especially in prior users), while estrogen-only therapy is associated with a marginal nonsignificant reduction in breast cancer risk. Both regimens lowered colorectal cancer incidence during active treatment. Early MHT initiation has no effect on cognitive function, whereas late initiation increases dementia risk. CONCLUSION: WHI findings underscore the importance of individualized, time-sensitive MHT use, with benefits and risks shaped by formulation, timing, and patient characteristics. These insights continue to inform evolving clinical practice.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lambrinoudaki I, Armeni E, Milli N, et al. Then and Now: What We Have Learned From the WHI. J Clin Endocrinol Metab. 2026. PMID: 41379766. doi:10.1210/clinem/dgaf638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。